MD; for the REVIVAL-3 Study Investigators* Background-Erythropoietin improves myocardial function in experimental models of myocardial infarction. The aim of the present study was to determine the value of erythropoietin in patients with acute ST-elevation myocardial infarction. Methods and Results-This randomized, double-blind study included 138 patients admitted with acute ST-elevation myocardial infarction and treated with primary percutaneous coronary intervention. Patients were randomly assigned to receive epoetin-␤ (3.33ϫ104 U, nϭ68) or placebo (nϭ70) immediately and at 24 and 48 hours after percutaneous coronary intervention. The primary end point was left ventricular ejection fraction after 6 months measured by MRI.
R eperfusion strategies, particularly primary percutaneous coronary interventions (PCI), have resulted in a remarkable increase in both short-and long-term survival of patients with acute ST-elevation myocardial infarction (STEMI). However, ischemia/reperfusion injury during STEMI is still a major unresolved problem. Novel approaches that protect and salvage injured myocardium constitute important advances in the therapy of ischemic diseases. Erythropoietin is a hypoxiainduced hormone produced in the kidney that stimulates hematopoiesis in the bone marrow. Recent studies have also shown important nonhematopoietic effects of erythropoietin.
A functional erythropoietin receptor was found in the cardiovascular system including endothelial cells 1 and cardiomyocytes. 2 Numerous ex vivo and in vivo studies have shown a protective role of human recombinant erythropoietin during ischemic and reperfusion in the heart with a reduction in infarct size and apoptosis. [3] [4] [5] [6] Erythropoietin prevented not only apoptosis of endothelial cells but also of cardiomyocytes by activating the PI3K/Akt pathway. 7 Moreover, activation of mitogen-activated kinase (MAPK) p38, p42/44, protein kinase C, and potassium channels mediates the protective effects of erythropoietin. 4 -6 In the longer-term erythropoietin may promote ischemia-induced neovascularization either by stimulating endothelial cells in situ or by mobilizing endothelial progenitor cells from the bone marrow. 8, 9 First clinical studies showed the safety and feasibility of erythropoietin or the long-acting erythropoietin analogue darbepoetin-␣ administration in patients with acute MI and stroke. 10, 11 Yet, the small number of patients enrolled did not allow defining the role of erythropoietin treatment in patients with AMI. Therefore, the purpose of this randomized, double-blind, placebocontrolled study was to assess the value of erythropoietin in patients with AMI.
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Methods
Patients
Patients were enrolled between January 2007 and November 2008 at the Deutsches Herzzentrum and 1st Medizinische Klinik rechts der Isar. Eligible patients were undergoing primary PCI for their first STEMI within 24 hours from symptom onset. Diagnosis of STEMI was established by chest pain lasting more Ն20 minutes, Ն0.1 mV of ST-segment elevation in Ն2 limb leads or Ն0.2 mV in Ն2 contiguous precordial leads, or new left bundle-branch block on the surface ECG. All patients had to have successful reperfusion by PCI and an angiographic left ventricular ejection fraction (LVEF) of Ͻ50% by visual estimation. Exclusion criteria were age Ͻ18 years or Ͼ80 years, congestive heart failure defined as Killip class Ͼ2, previous MI, malignancies or other comorbid conditions with life expectancy Ͻ1 year, thrombolysis for the index infarction, uncontrolled hypertension unresponsive to therapy, epilepsy, hematologic disorders and relevant hematologic deviations, renal insufficiency (GFR Ͻ30 mL/min), chronic liver disease (GOT Ͼ5-fold of the normal range), pericarditis, any contraindication to MRI, known allergy to erythropoietin, and known or suspected pregnancy. The study protocol was approved by the institutional ethics committee responsible for both participating centers, and all patients gave written informed consent for participation in the study. All patients received 600 mg of clopidogrel orally, 500 mg aspirin, and unfractionated heparin with or without abciximab intravenously. Heparin was given as a bolus of 140 IU or 70 IU in case of additional abciximab (0.25 mg/kg body weight bolus, followed by an infusion of 0.125 g/kg per min for 12 hours).
Sealed envelopes containing blinded treatment code were used for random assignment. The study drug was given at 3 distinct time points: immediately after successful PCI in the catheterization laboratory and at 24 hours and 48 hours after random assignment. Each time, patients received either 3.33ϫ10 4 IU of recombinant human epoetin-␤ (NeoRecormon; F. Hoffmann-La Roche, Basel, Switzerland) or a matching placebo intravenously for 30 minutes. Postinterventional antithrombotic therapy consisted of clopidogrel 75 mg twice a day for 3 days followed by 75 mg/d for at least 6 months. Aspirin 100 mg twice a day was recommended indefinitely. Other cardiac medications were prescribed at the discretion of the treating physician.
Magnetic Resonance Imaging
MRI was performed 5 days and 6 months after random assignment in the supine position with a 1.5-T clinical scanner (Siemens Sonata; Erlangen, Germany, in the Klinikum rechts der Isar, and Siemens Avanto, Erlangen, in the Deutsches Herzzentrum) equipped with a dedicated cardiac phased-array surface coil. All images were obtained during repeated breath-holds and were gated to the ECG. Cine images of the entire LV were acquired in contiguous short-axis views using a balanced steady state-free precession MR sequence with a slice thickness of 8 mm. A gadolinium-based contrast agent (gadolinium-diethylene-triamine-pentaacetic acid; Gd-DTPA, Magnevist, Schering-AG, Munich, Germany) was administered intravenously at a dose of 0.2 mmol/kg body weight. After 20 minutes, contrast-enhanced T1-weighted images were acquired in contiguous short-axis views of the entire LV with the use of a segmented inversion-recovery spoiled gradient (echo) pulse sequence with a slice thickness of 8 mm. The inversion time was individually adapted to null normal myocardium. Contrast-enhanced MR imaging was analyzed in random order by an experienced observer who was unaware of the patient's identity and treatment. Epicardial and endocardial contours were outlined on all short-axis images to calculate the total myocardial volume. Myocardial contrast enhancement was manually traced to determine the infarct volume. Myocardial infarct size was quantified in percent of the LV by dividing the myocardial enhancement volume by the total myocardial volume. To determine the LVEF, the LV borders on the short-axis cine images were outlined and LVEF was calculated by subtracting the volume at end systole from the volume at end diastole divided by the volume at end diastole.
Angiographic Evaluation
We used nonionic contrast medium (Imeron, Altana, Germany) in all patients. LV and coronary angiograms performed before random assignment and at 6-month follow-up were assessed off-line in the Angiographic Core Laboratory by personnel unaware of treatment group allocation. Offline quantitative assessment of angiograms was performed with the use of an automated edge detection system (CMS Version 6.0.10.0, Medis Medical Imaging Systems, Nuenen, The Netherlands). Global LVEF was determined by the area-length method. We used the centerline method to quantify regional LV wall motion by measuring the number of chords within the region of interest showing hypokinesis. 12
Follow-Up Protocol
In-hospital follow-up protocol consisted of serial ECG recordings and routine laboratory parameters. Serum creatine kinase, differential blood count, and routine laboratory values were determined in the clinical chemistry laboratory before, daily after random assignment, and at follow-up. A phone contact was performed 30 days after enrollment in the study. Patients with complaints underwent an ECG, a complete clinical examination, and laboratory check-up. Six-month follow-up included a clinical check-up, ECG, MRI, and angiography.
Definitions and Study End Points
The primary end point of this study was LVEF 6 months after random assignment measured by MRI. Secondary end points were changes in LVEF and infarct size between 5 days to 6 months after random assignment measured by MRI. Other parameters assessed were LV volumes and infarct size in MRI, LVEF, and number of hypokinetic chords in angiography and major adverse cardiac and cerebrovascular events at 30 days and 6 months (composite of death, recurrent MI, revascularization of the infarct-related artery, and stroke).
Diagnosis of recurrent infarction was based on the presence of at least 2 of the following criteria: new ST-segment changes and an increase in creatine kinase and creatine kinase-MB of Ն50% over the previous level in at least 2 samples reaching Ն3 times the upper limit of normal. All events were adjudicated and classified by an event adjudication committee blinded to the assigned treatment group.
Statistical Analysis
Sample size calculation was based on the assumption that erythropoietin is associated with an EF at 6 months 5% higher than in the control group (50Ϯ9% versus 45Ϯ9%). With a 2-sided ␣-level of 0.05 and a power of 80%, 52 patients were required in each group. We enrolled 138 patients to accommodate for possible missing investigations and withdrawals. All analyses were done on the basis of the full analysis set using all available data from patients as randomly assigned. Categorical data are presented as counts or proportions (%). Continuous data are presented as meanϮstandard deviation. Differences between the groups were assessed using 2 or Fisher exact test for categorical data and t test for continuous data.
Heterogeneity of treatment differences across various subsets was checked by assessing the interaction between assigned treatment and variables defining the subset with respect to the end point of interest. Survival analysis was made by applying the Kaplan-Meier method. The difference in the composite event rate between the 2 study groups was checked for significance by means of a Cox proportional hazards model, which also allowed the calculation of the respective hazard ratio with its 95% confidence interval. A 2-tailed probability value Ͻ.05 was considered to indicate statistical significance. We used S-Plus version 4.5 (S-PLUS, Insightful Corp, Seattle, Wash) for statistical analyses.
Results
One hundred thirty-eight patients were included in the study: 68 received epoetin-␤ and 70 received placebo (Figure 1 ). All patients received the randomly assigned medication. Baseline characteristics of the patients are shown in Table 1 and infarct related characteristics are shown in Table 2 . Baseline angiographic LVEF was 46% in both groups. Drug-eluting stents were implanted in 93% of the patients in the epoetin group and 95% of the patients in the placebo group. Thrombolysis in myocardial infarction (TIMI) grade 3 flow was restored in 93% of patients in the epoetin group and 90% of patients in the placebo group. Baseline reticulocyte count was similar in both groups on study entry (11.3Ϯ3.8ϫ10 
LV Function and Infarct Size
MRI analysis was completed in 87% of patients at day 5 and in 78% of the patients at 6 months ( Figure 1) . None of the patients underwent recurrent MI. The primary end point LVEF on MRI after 6 months was 52% in both groups. Similarly, there were no differences between the groups regarding changes in LVEF, infarct size, and end-systolic or end-diastolic volume indices if the analysis is confined to patients with both follow-up examinations (Table 3) . Moreover, the primary end point did not differ significantly according to the study treatment in any of the prespecified subgroups (age, renal function, reperfusion time, angiographic EF; data not shown). Six-month angiography was achieved in 84% of the patients receiving epoetin and 87% receiving placebo. There were no significant differences regarding both global and regional LV function between the 2 groups if the analysis is confined to patients with both baseline and follow-up examinations (Table 3) .
Clinical Outcomes
Clinical follow-up was complete in all patients. During the 30-day follow-up, 1 patient in the epoetin group died as the result of suspected pulmonary embolism and 2 in the placebo group of cardiogenic shock. Within 30 days, 4 patients in the epoetin group died or had MI, revascularization of the infarct-related artery, or stroke as compared with 3 patients in the placebo group.
Between 30 days and 6 months, 2 additional patients died: 1 patient in the epoetin group as the result of septic shock and 1 patient in the placebo group (sudden cardiac death). A detailed list of adverse events during the entire 6-month period is shown in Table 4 . Figure 2 shows 6-month eventfree survival curves.
Discussion
This is the first study investigating the effect of erythropoietin in patients with STEMI undergoing primary PCI. We found no beneficial effect of erythropoietin on LVEF or infarct size. On the contrary, there was a trend toward a higher adverse event rate with erythropoietin at 6 months. Recent evidence suggests that erythropoietin plays a protective role in vascular diseases by nonerythropoietic effects. Ischemia/reperfusion experiments in rat heart show large infarct size reduction after treatment with erythropoietin. The favorable effect of these erythropoietin-related changes may be explained by protection from apoptosis and antioxidative properties. 3 Other benefits may be related to the proangiogenic potential of erythropoietin. 13 Despite promising results in rodents, erythropoietin did not reduce infarct size in porcine models. 14 Recently, high levels of endogenous erythropoietin in patients with acute MI who underwent primary PCI were found to be associated with smaller infarcts. 15 Moreover, knockout studies of the nonerythropoietic erythropoietin receptor have shown a protective role of the erythropoietin receptor in models of MI. Thus, overriding the endogenous protective role of erythropoietin by exogenously applied erythropoietin may not improve myocardial function Data are presented as n (%), meanϮstandard deviation, or median ͓95% confidence interval͔.
IABP indicates intraaortic balloon pump; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LMCA, left main coronary artery; RCA, right coronary artery; and TIMI, Thrombolysis In Myocardial Infarction. Data are presented as n (%).
IRA indicates infarct-related artery.
in patients with STEMI. In mildly anemic chronic heart failure patients, normalization of hemoglobin levels with erythropoietin was shown to have a positive effect on LVEF. 16 In addition to the correction of anemia, other protective effects of erythropoietin may contribute to this improvement in myocardial function. Also, in several experimental models of chronic heart failure, erythropoietin has been described to improve cardiac function. 8, 17 Our study shows that epoetin-␤ in addition to mechanical reperfusion does not improve myocardial function in a clinical setting. Although not significant, the slight increase in EF between day 5 and 6 months may encourage further research in this area. In contrast, even though our study was not powered for clinical end points, the trend toward a higher event rate advises caution regarding the application of epoetin in patients with STEMI. These results are in line with previous observations rising concerns about the use of erythropoiesis-stimulating agents. Several studies have shown rapid tumor growth or shortened survival of patients with different cancers that received erythropoietin. Moreover, erythropoietin is associated with an increased risk of venous thromboembolic phenomena and mortality. 18 Thus, our study endorses the caution necessary when clinical trials with erythropoietin are conducted.
The regimen we used was based on experimental studies as well as on clinical studies that have shown that high-dose, short-term erythropoietin improved clinical outcome in patients with acute stroke. 11 Rat studies used dosages of 350 to 5000 IU/kg. This would translate into 24 500 to 350 000 IU in humans. The applied cumulative dosage of 99 000 IU in our study has been among the highest doses tested in clinical trials and proven to be well tolerated. 11, 19 Because erythropoietin appears to improve myocardial function in rodents but not in humans, differences in the application of erythropoietin must be considered. In general, the rat studies start treatment earlier than in the present study. However, the promptness of treatment in the present study was as good as it could be achieved in a real world setting. Moreover, it should be noted that the anatomy and physiology of rodents and humans differ greatly.
Erythropoietin is widely used for the treatment of renal anemia to enhance erythropoiesis. In line with previous studies, the effectiveness of the treatment in our study was shown by a significant increase in circulating reticulocytes. Yet, the present trial demonstrated that epoetin did not enhance myocardial regeneration, decrease infarct size, or improve LV function after acute MI.
The negative finding of the current study could be explained by several reasons. The infarct size significantly decreased 6 months after acute MI in both epoetin and placebo groups. Likewise, LVEF increased similarly in both groups. Therefore, our data confirm previous studies of functional recovery after acute MI in patients undergoing primary PCI and optimized drug therapy. 20 In contrast to the experimental studies, the effect of erythropoietin treatment in the present study was not sufficient to further enhance this improvement. The reasons why erythropoietin appears to improve cardiac function in experimental models of MI in rodents may be due to differences in anatomy or physiology or in timing or dosage of erythropoietin. In the rat studies, erythropoietin was applied earlier; however, we applied the study drug as early as possible in a clinical setting. Dosages that have been shown promise in animal models ranged from 5000 to 10 000 U/kg. Although the dosage we used lies within this range, we cannot exclude that in humans higher concentrations of erythropoietin are required to achieve cardioprotection.
In conclusion, in patients with STEMI treated with primary PCI, erythropoietin does not improve LVEF or reduce infarct size. Clinical adverse events may be increased after treatment with erythropoietin. 
